{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/influenza-seasonal/prescribing-information/oseltamivir/","result":{"pageContext":{"chapter":{"id":"418c695e-c703-5e30-9ec2-9bf2afeb6001","slug":"oseltamivir","fullItemName":"Oseltamivir","depth":2,"htmlHeader":"<!-- begin field 5aafcffd-e57f-4e9b-bde9-629cabefec2c --><h2>Oseltamivir</h2><!-- end field 5aafcffd-e57f-4e9b-bde9-629cabefec2c -->","summary":"","htmlStringContent":"<!-- begin item 1f482af5-1e25-4d28-885d-129923be91eb --><!-- end item 1f482af5-1e25-4d28-885d-129923be91eb -->","topic":{"id":"7143131b-dc98-5d14-aef2-f50114a27d13","topicId":"c00149e5-18ab-49c6-8576-089384091df2","topicName":"Influenza - seasonal","slug":"influenza-seasonal","lastRevised":"Last revised in August 2020","chapters":[{"id":"415ca83c-583b-5dd7-8ce7-a67a72325836","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"39d27467-6801-59da-a28b-29a9a1aa848d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7326279e-c8e9-5783-9cb0-433a2e0c5061","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ecde5124-7df2-5d70-921e-cfa13a752476","slug":"changes","fullItemName":"Changes"},{"id":"b4d67dc6-a391-5644-a3a4-89c1c0c49e3f","slug":"update","fullItemName":"Update"}]},{"id":"3b2a94ae-a366-5ff9-8a35-6f8eb63736a1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8b66965c-fc03-5267-ac06-f0edc2bf81ea","slug":"goals","fullItemName":"Goals"},{"id":"32bc1d45-c0ea-55ed-8723-fdbf13b7196e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c5aa9558-010a-5b32-b95a-40f647ef373e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b9c5c598-f72e-505f-b951-cbe710a6af02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0c6ad8d-5845-5dfd-b2d0-b04bb5395c62","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"48e0bfcd-fd33-552c-b052-28533a176218","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"feb6e56c-e4f6-57f4-bbee-0876089197e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bc17d7e2-a53a-595c-9f57-7080c9814001","slug":"definition","fullItemName":"Definition"},{"id":"d0475ee5-11e2-5ad5-8628-4f513e50236f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0aabed4-a912-518e-9257-8653bc7541e4","slug":"complications","fullItemName":"Complications"}]},{"id":"f81fdd28-028a-5558-92b2-90a1569692bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dcd79bc4-67e6-52b5-af13-ab18772e4c55","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4da6c7b5-c872-551a-aff9-100bef3041ca","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b540d9e5-48f5-5b1c-a8b1-8a37d951449f","fullItemName":"Management","slug":"management","subChapters":[{"id":"9cbc6ee5-b0da-5b46-9ce4-3704f7cf24a9","slug":"treating-influenza","fullItemName":"Scenario: Treating influenza"},{"id":"b82606d4-79c4-5b96-84cd-115c371c80b4","slug":"post-exposure-prophylaxis","fullItemName":"Scenario: Post-exposure prophylaxis"}]},{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"418c695e-c703-5e30-9ec2-9bf2afeb6001","slug":"oseltamivir","fullItemName":"Oseltamivir"},{"id":"370b7394-2bad-5d4f-ac2a-06de67bbefea","slug":"zanamivir","fullItemName":"Zanamivir"}]},{"id":"83f51ef5-d6f9-5101-849d-c72bd5975126","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fe85159c-da36-5171-9b52-88d8edd9ee77","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"46f280be-d769-501b-905f-789bbf2d8454","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9904923d-c7de-53aa-8253-15c9392ece2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3790de44-d79a-5486-b053-d09c6dccc2cc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e631b66-3030-5dd0-97e7-7504198b5a14","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ab624014-37fa-5613-976c-e2ffa65a7e90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b4d3fc-b6de-5df4-ad98-bf9ea439e342","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"eb2950d7-1190-51e7-b9f7-a3b7f90c929b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1403bca9-bf56-4f13-a21a-aa1e00b7f0a9 --><h3>Contraindications and cautions</h3><!-- end field 1403bca9-bf56-4f13-a21a-aa1e00b7f0a9 -->","summary":"","htmlStringContent":"<!-- begin item aeb4456a-29ce-4f72-b980-aa1e00b7f00b --><!-- begin field 5e16e78d-1297-40ba-9f4f-aa1e00b7f0a9 --><ul><li><strong>Do not prescribe oseltamivir in premature infants. </strong></li><li><strong>Prescribe oseltamivir with caution to people with renal impairment </strong>— dosage adjustments may be necessary. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 5e16e78d-1297-40ba-9f4f-aa1e00b7f0a9 --><!-- end item aeb4456a-29ce-4f72-b980-aa1e00b7f00b -->","subChapters":[]},{"id":"211d8582-6989-59af-9863-9eef2ad930d6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2de86bbf-0388-45fc-9774-aa1e00b8044f --><h3>Adverse effects</h3><!-- end field 2de86bbf-0388-45fc-9774-aa1e00b8044f -->","summary":"","htmlStringContent":"<!-- begin item 485bb2f9-f243-4d32-a9b1-aa1e00b80428 --><!-- begin field 022da5eb-ed40-49fd-8baf-aa1e00b8044f --><ul><li><strong>Common adverse effects include:</strong><ul><li>Abdominal pain.</li><li>Conjunctivitis.</li><li>Dizziness, vertigo.</li><li>Earache.</li><li>Headache.</li><li>Nausea, vomiting.</li><li>Otitis media.</li></ul></li><li><strong>Uncommon adverse effects include:</strong><ul><li>Arrhythmia.</li><li>Consciousness impaired.</li><li>Skin reactions.</li></ul></li><li><strong>Rare adverse effects include: </strong><ul><li>Abnormal behaviour abnormal. </li><li>Angioedema. </li><li>Anxiety, confusion, delirium, delusions, hallucination, self-injurious behaviour.</li><li>Haemorrhage. </li><li>Hepatic disorders. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 022da5eb-ed40-49fd-8baf-aa1e00b8044f --><!-- end item 485bb2f9-f243-4d32-a9b1-aa1e00b80428 -->","subChapters":[]},{"id":"3655d09c-832a-5529-96f3-aff0926688d7","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 6b47740d-c1e8-49f8-9968-aa1e00b813d1 --><h3>Pregnancy and breastfeeding</h3><!-- end field 6b47740d-c1e8-49f8-9968-aa1e00b813d1 -->","summary":"","htmlStringContent":"<!-- begin item 76301cbe-6197-4a6e-9d6e-aa1e00b813ac --><!-- begin field 31e294e8-fa4d-4534-bc85-aa1e00b813d1 --><ul><li><strong>Pregnancy</strong><ul><li>Safety data are limited, however recent studies suggest there is no evidence of harm in pregnant women treated with oseltamivir.</li><li>Oseltamivir can be used in women who are pregnant when the potential benefit outweighs the risk.<ul><li>Oseltamivir remains the first line option for the vast majority of pregnant women with influenza, including during seasons that are dominated by influenza A(H1N1).</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Oseltamivir and its active metabolite are excreted in breastmilk. </li><li>Safety data are limited, however oseltamivir can be used in women who are breastfeeding when the potential benefit outweighs the risk (for example, during a pandemic).</li><li>Oseltamivir is the preferred drug in women who are breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>] </p><!-- end field 31e294e8-fa4d-4534-bc85-aa1e00b813d1 --><!-- end item 76301cbe-6197-4a6e-9d6e-aa1e00b813ac -->","subChapters":[]},{"id":"f5d75a9b-53c1-5152-8147-36c37aa3bca0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d41d778c-3a39-4d83-a12f-aa1e00b81e7b --><h3>Drug interactions</h3><!-- end field d41d778c-3a39-4d83-a12f-aa1e00b81e7b -->","summary":"","htmlStringContent":"<!-- begin item c216c487-b501-4945-9a9b-aa1e00b81e54 --><!-- begin field 72a0b645-741d-4a83-aa67-aa1e00b81e7b --><ul><li>Leflunomide/terflunomide — levels of the active metabolite of oseltamivir may be increased. Monitor for adverse effects and adjust oseltamivir dose if required. </li><li>Tolvaptan — levels of the active metabolite of oseltamivir may be increased. Monitor for adverse effects and adjust oseltamivir dose if required. </li><li>Warfarin — isolated case of raised INRs have been reported.  </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Preston, 2016</a>]</p><!-- end field 72a0b645-741d-4a83-aa67-aa1e00b81e7b --><!-- end item c216c487-b501-4945-9a9b-aa1e00b81e54 -->","subChapters":[]},{"id":"67e21ce6-8c58-596f-b845-1ea9b0629f49","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 923befc3-c717-4b4c-b87e-aa2a00d0cb80 --><h3>Dose</h3><!-- end field 923befc3-c717-4b4c-b87e-aa2a00d0cb80 -->","summary":"","htmlStringContent":"<!-- begin item cc0d20cf-e8e9-42d5-bf4f-aa2a00d0caf8 --><!-- begin field b41ed897-73ff-4e10-820f-aa2a00d0cb80 --><p><strong>Table 1. </strong>Recommended doses of oseltamivir.</p><table><thead><tr><th colspan=\"1\"> </th><th colspan=\"1\">Treatment of influenza</th><th colspan=\"1\">Post exposure prophylaxis</th></tr></thead><tbody><tr><td colspan=\"1\"><strong>Adults (aged 13 years and over)</strong></td><td colspan=\"1\">75 mg twice a day for 5 days</td><td colspan=\"1\"> 75 mg once a day for 10 days (for up to 6 weeks during an epidemic)</td></tr><tr><td colspan=\"3\"><strong>Children aged 1–12 years (dose is based on body weight)</strong></td></tr><tr><td colspan=\"1\">≤ 15 kg</td><td colspan=\"1\">30 mg twice a day</td><td colspan=\"1\">30 mg once a day</td></tr><tr><td colspan=\"1\">>15–23 kg</td><td colspan=\"1\">45 mg twice a day</td><td colspan=\"1\">45 mg once a day</td></tr><tr><td colspan=\"1\">> 23–40 kg</td><td colspan=\"1\">60 mg twice a day</td><td colspan=\"1\">60 mg once a day</td></tr><tr><td colspan=\"1\">>40 kg </td><td colspan=\"1\">75 mg twice a day</td><td colspan=\"1\">75 mg once a day</td></tr><tr><td colspan=\"3\"><strong>Children aged under 1 year</strong></td></tr><tr><td colspan=\"1\">0–12 months</td><td colspan=\"1\">3 mg/kg twice a day</td><td colspan=\"1\">3 mg/kg once a day</td></tr><tr><td colspan=\"3\"><strong>Premature</strong></td></tr><tr><td colspan=\"1\">< 36 weeks post conceptual age</td><td colspan=\"1\">1 mg/kg twice a day*</td><td colspan=\"1\">**</td></tr><tr><td colspan=\"3\"><strong>Renal impairment for adults and children aged 13–17 years (dose is based on creatinine clearance)</strong></td></tr><tr><td colspan=\"1\">> 60 mL/min</td><td colspan=\"1\">75 mg twice a day</td><td colspan=\"1\">75 mg once a day</td></tr><tr><td colspan=\"1\">30–60 mL/min</td><td colspan=\"1\">30 mg twice a day</td><td colspan=\"1\">30 mg once a day </td></tr><tr><td colspan=\"1\">11– 30 mL/min</td><td colspan=\"1\">30 mg once a day</td><td colspan=\"1\">30 mg once every second day</td></tr><tr><td colspan=\"1\">≤ 10 mL/min </td><td colspan=\"1\">30 mg ONCE</td><td colspan=\"1\">30 mg ONCE, repeated after 7 days</td></tr><tr><td colspan=\"3\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>]</td></tr><tr><td colspan=\"3\">* This is an unlicensed use of oseltamivir; ** there is currently no publicly available dosing information for oseltamivir prophylaxis in pre-term infants, and so it is outside the product licence</td></tr></tbody></table><!-- end field b41ed897-73ff-4e10-820f-aa2a00d0cb80 --><!-- end item cc0d20cf-e8e9-42d5-bf4f-aa2a00d0caf8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}